Home MarketBiocon Ltd.

Biocon Ltd. Stock Info: As on 2018-05-24 15:59:56

Nse

645.35

7.15(1.12%)
Change%
52 Week Range
294.74
25.00
677.90
30.00
Open642.00
Day's Range574.38 - 702.02
Value Traded (in ₹ Cr.) 59.30

Bse

645.00

6.15(0.96%)
Change %
52 Week Range
294.71
25.00
677.85
30.00
Open641.80
Day's Range574.97 - 702.74
Value Traded (in ₹ Cr.) 8.07

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 125,382,540.00 20.90%
IndianPromoters 238,625,298.00 39.77%
Mutual Funds/UTI 14,346,394.00 2.39%
FII 101,922,325.00 16.99%
Employee 0.00 0.00%
Public 68,419,046.00 11.40%
Government 0.00 0.00%
Others 33,035,844.00 5.51%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 8.76
Basic EPS (Rs.) 26.45
Cash EPS 33.49
BVPerShare Excl 327.01
Operating Revenue 129.40
PBDITPerShare 34.51
Dividend 1.00
NPPerShare 25.97
Current Ratio 3.37
Quick Ratio 2.61
PriceToBV 3.47
Earnings 0.02
PBDIT Margin 26.67
PBT Margin 20.71
NP Margin 20.06
Return On Assets 6.95
Retention Ratios 0.00
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 2,686.70
Total Expenses 2,150.90
EBITDA 690.20
PBT 536.20
PAT 519.30
Net Income 519.30
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 1,308.80
Total Expenses 1,162.30
EBITDA 81.00
PBT 146.60
PAT 115.60
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 100.00
Net worth 6,541.10
Investments 3,888.20
Total Liability 7,468.90
Total debt 132.40
Net block 1,178.80
Total Assets 7,468.90
Parameter Mar-17 (₹ Cr.) 6M % change
Total share capital 100.00
Net worth 3,288.50
Investments 610.80
Total Liability 4,398.90
Total debt 362.00
Net block 1,110.00
Total Assets 4,398.90
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 185.80
Cash from investing activities 110.40
Cash from financing activities -238.30
Net change in cash 51.50

Stock Held By Mutual Fund Schemes

Corporate Details

About Management

2002 -The Biocon India group promoter of Biocon India Ltd. Ms Kiran Mazumdar Shaw, Chairman and Managing Director of Biocon India Group. -Biocon India appointed DSP Merrill Lynch and Kotak Mahindra for its Rs 150-crore IPO scheduled for June next year. Biocon-Shantha Biotech, the 50:50 joint venture between Biocon India and Shantha Biotechnics, focuses on the domestic and global human insulin markets by maximizing on R&D manufacturing and regulatory capacities of the two companies. 2003 -ICICI Venture offloads 10-pc stake in Biocon 2004 -Clinigene International inaugurates human pharmacology unit for clinical trials -Comes out with an Initial Public Offering (IPO) of 10 million shares at a price of Rs 315 per share for a face value of Rs 5 per share which constitutes 10% of the post-issue capital (Rs 100 crore), listed at Rs 425 -Biocon Ltd has entered into a nine-year export contract with US major Bristol-Myers Squibb Co to supply the bulk form of its recombinant human insulin -Biocon forays into lifestyle drugs market -Biocon's clinical research arm, Clinigene International Pvt Ltd. re-accredited by the College of American Pathologists (CAP) following a recent inspection -Biocon Ltd has informed that in an unusual commercial transaction between Cuba and USA, a Californian Biotechnology Company, CancerVax Corporation received a rare US Government approval to License three experimental cancer drugs from a leading Cuban Institute (CIMAB) -Biocon said on July 26 that its Cuban partner CIMAB (Centre for Molecular Immunology) in the joint venture with Biocon Biopharmaceuticals will be able to license out three experimental cancer drugs to a Californian Biotechnology company, CancerVax Corporation -Biocon, Syngene enters into Research Agreement with Novartis Institutes for Biomedical Research Inc -Biocon unveils new bio insulin 2005 Biocon signs MoU with Karolinska Institute. -Ms Kiran Mazumdar-Shaw, CMD of Biocon Ltd, has been honoured with the Corporate Leadership Award 2005 of the American India Foundation (AIF) -Biocon signs Licensing agreement with Bentley Pharmaceuticals Inc. 2006 -Biocon ties up with ICICI Prudential Life Insurance -Biocon concludes Phase-IV trials of Insugem 2007 -Biocon Ltd and Abu Dhabi based pharmaceutical company Neopharma have signed an MOU to establish a JV to manufacture and market a range of Bio-pharmaceuticals for the GCC countries (Gulf Cooperation Council). -Biocon Ltd on March 14, 2007 has announced that its subsidiary Company Syngene has entered into a research partnership with Bristol-Myers Squibb. -Biocon signs MOU with Neopharma for a JV 2008 -The Company has issued Bonus Shares in the Ratio of 1:1. 2009 - Biocon and Amylin Pharmaceuitcals Inc have entered into an exclusive agreement to jointly develop, commercialise and manufacture a new peptide therapeutic for potential treatment of diabetes. The two companies will share development costs. -Biocon launches BASALOG - long lasting basal insulin for Type 1 & Type 2 Diabetics -Biocon joins hands with Amylin Pharmaceuticals -Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management 2010 - Biocon has launched its new 'comprehensive care' division, dedicated to provide affordable solutions to critical illnesses such as nosocomial infections, post surgical complications, trauma and medical emergencies. - Biocon has signed an agreement with Teleradiology Solutions to provide teleradiology reporting services to Clinigene, Biocon's clinical research arm. 2011 -Biocon announces preliminary data on its novel oral insulin drug candidate -Biocon announces project commencement for first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell, Malaysia -Biocon launches INSUPenr, a convenient and affordable reusable insulin delivery device -Clinigene International Enters into Collaborative Clinical Research Services -Biocon wins Biospectrum BioPharma Company of the year award -Biocon wins Best Design and Information Award for the Healthcare Sector at Bangalore India Bio 2012 -Biocon wins Excellence in Environmental Management Award -Biocon wins Best Exhibitor Award in the category of Biocontent and Information at Bangalore India Bio -Biocon wins Golden Peacock National Quality Award -Biocon Research Centre Inaugurated by Nobel Laureate Prof Kurt Wthrich -Biocon announces that it has entered into an option agreement with Bristol-Myers Squibb for Biocon's IN-105, an oral insulin drug candidate 2013 -"Biocon Launches ALZUMAb - a First in Class Novel Biologic Treatment for Psoriasis Patients in India". -"Biocon Enhances Partnership with Mylan through Strategic Collaboration for Insulin Products." -"Biocon Partners with CytoSorbents to Market CytoSorbr-A First-in-Class Therapy for Sepsis Management". -"Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the Science Magazine". -Biocon the Top Ten Most Admired Companies in the Pharma & Healthcare Sector. -Biocon wins Best Design and Innovation Exhibitor Award at Bangalore India Bio. 2014 -Biocon has been conferred with the Sir J C Bose Memorial Award 2013 (Institutional category) by Indian Science Monitor (ISM) for its contribution in the field of Biotechnology, with special reference to the launch of ALZUMAb (Itolizumab). -Biocon Foundation gets 'Asia Best CSR Practices Award 2014 for ''Cervical Cancer Screening Programme''. -Biocon wins Thomson Reuters India Innovation Awards 2014 -Biocon launches drug for breast cancer treatment -Biocon partners with Advaxis for novel cancer immunotherapy -Biocon launches flagship program in collaboration with KGI 2015 -Biocon Foundation bags WHO award -Biocon Strengthens its Presence in Mexico; Receives Approval for Insulin Glargine through its partner PiSA Farmaceutica -Biocon's CRO Arm Syngene Seeks Approval for IPO, Files DRHP -Biocon's Nationwide 'Winning with Diabetes' Campaign Raises Awareness on Disease Prevention & Management -NeoBiocon Partners with Novartis to offer Vildagliptin for Diabetics in UAE -Biocon launches new Hepatitis-C drug in India - Biocon is the Only Asian Company to be ranked in Top 20 Global Biotech Employers -Biocon Inaugurates World Class Devices Facility & Introduces Basalog One 2016 -Biocon Academy Introduces First Of Its Kind Career Advancement Program in 'Quality Control Microbiology' in Collaboration with BITS Pilani -Biocon receives Karnataka govt nod for Rs 1,060 cr plant -Biocon launches Insulin Glargine in Japan 2017 - U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab - Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia - Biocon Foundation & Department of Medical, Health & Family Welfare, Govt. of Karnataka Collaborate to Set Up Smart eLAJ Clinics in Karnataka - Kiran Mazumdar-Shaw Felicitated with 'AWSM Award for Excellence 2017' by The Feinstein Institute for Medical Research, USA - Company Statement on Media Reports on USFDA 483s - Biocon's Clarification post media reports on Biocon on the FDA list for not paying facility fee. Biocon has paid Facility Fee for its API facility to USFDA in Sep 2017 - Biocon Launches KRABEVAr - Biosimilar Bevacizumab for Treating Several Types of Cancer in India - Biocon's Drug Product Facility Receives EIR with VAI status, Inspection Closed

Registered Office

Plot 213-215, IDA Phase-II, Pashamylaram,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.